A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Ovarian cancer cannot grow without recruiting new blood vessels. Studies in humans have
identified a novel cell population, termed vascular leukocytes (VLCs). While VLCs are not
cancer cells, they support the growth of ovarian cancer cells by stimulating the growth of
new blood vessels which provide the cancer with nutrients. VLCs make a protein termed CD52.
An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the
CD52 protein has been successfully used to treat certain lymphomas (a type of blood cell
cancer) that make CD52 protein. The purpose of this study is to determine if Alemtuzumab
given subcutaneously (under the skin)can be safely given to patients with ovarian, fallopian,
or primary peritoneal cancers to kill VLCs and determine if Alemtuzumab, by eliminating VLCs,
can restrict tumor growth or increase response rates to chemotherapy given after the
discontinuation of chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center